The term hyperplasia refers to an increase in the amount of organic tissue resulting from cellular proliferation. It frequently leads to the gross enlargement of an organ. Hyperplasia is generally a reversible, physiological, or pathological response to a specific stimulus (such as hormonal surges, chronic irritation, or compensatory demand). Crucially, the cells in hyperplasia remain normal in appearance and organization, distinguishing it from dysplasia (abnormal cell changes) and neoplasia (cancerous or benign tumors). Common clinical manifestations include Benign Prostatic Hyperplasia (BPH) and endometrial hyperplasia.
The roots combine directly to mean “excessive formation” or “overgrowth.” The term emerged in the mid-19th century as microscopic pathology evolved, allowing physicians to distinguish between tissue enlargement caused by larger cells (hypertrophy) versus more numerous cells (hyperplasia).
Transurethral electrosurgical resection of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included) (TURP for BPH)
Level IV - Surgical pathology, gross and microscopic examination (the standard path evaluation to confirm hyperplasia vs. neoplasia)
⚠️ Coding Note: Context is critical when coding hyperplasia, as it manifests differently depending on the organ system. For Benign Prostatic Hyperplasia (BPH), ICD-10 requires knowing if the patient has associated Lower Urinary Tract Symptoms (LUTS) to choose between N40.0 and N40.1. If N40.1 is used, an additional code must be assigned to identify the specific symptoms (e.g., incomplete bladder emptying, urinary frequency). For endometrial hyperplasia, coders must look closely at pathology reports to determine if it is benign (N85.01) or if there is atypia/EIN (N85.02), as the latter carries a significantly higher risk for malignancy and drives different clinical management.